Loading...
Market
Vaccine type with highest adverse events rate in US for 2024?
2
Resolution / Starting Odds
mRNA vaccines • 25%
Novavax • 25%
Janssen • 25%
Other • 25%
Official reports from VAERS or similar databases
Story
Study by Drs. Knapp and Bhargava Finds More Hospitalizations for mRNA Vaccine Adverse Events Than COVID-19 Infections
Oct 20, 2024, 06:58 AM
A recent study led by leading American researchers Drs. Johannes D. Knapp and Aditi Bhargava, PhD, has found that hospitals treated significantly more patients for adverse events related to mRNA COVID-19 vaccines compared to unvaccinated patients with COVID-19 infections. This study highlights concerns about the safety of mRNA vaccines, which have been widely promoted by public health agencies. The findings have sparked discussions about the potential biases of US public health agencies in favoring mRNA vaccines over other types, such as Novavax and Janssen.
View original story
Similar markets
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Novavax • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
GeoVax COVID-19 vaccine • 33%
Moderna mRNA influenza vaccine • 33%
Pfizer COVID-19 vaccine • 33%
mRNA vaccines • 25%
Non-mRNA vaccines • 25%
No specific recommendation • 25%
Other vaccine types • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
0-17 years • 25%
18-49 years • 25%
50-64 years • 25%
65+ years • 25%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
Less than 80,000 • 25%
80,000 to 90,000 • 25%
90,000 to 100,000 • 25%
More than 100,000 • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%